Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor.
| Condition | Intervention | Phase |
|---|---|---|
|
Renal Cell Carcinoma |
Biological: autologous human tumor-derived HSPPC-96 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized Phase II Study Investigating the Route of Administration of Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma |
| Estimated Enrollment: | 40 |
| Study Start Date: | July 2002 |
| Study Completion Date: | December 2005 |
| Primary Completion Date: | December 2005 (Final data collection date for primary outcome measure) |
The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor. The study is being conducted in Houston, Texas with patients enrolled into one of two treatment arms. The two treatment arms are either subcutaneous injection or intradermal injection, both with HSPPC-96. To be treated with HSPPC-96 patients must undergo surgery to remove the kidney tumor and a portion of this tissue will be sent to Antigenics' manufacturing facility for processing.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Suspected metastatic renal cell carcinoma (AJCC Stage IV) with intact primary tumor
- No previous therapy for metastatic renal cell carcinoma
- Measurable disease (RECIST criteria)
- Primary tumor greater than or equal to 7cm on CT or MRI
- ECOG performance status 0-1
- At least 18 years old
- Life expectancy > 3 months
- Adequate cardiac function (NYHA I-II)
- Not pregnant
- Provide written informed consent
- Absence of multiple liver metastases, brain or threatening bone metastases (axial skeleton and/or pathological features)
- Planned complete nephrectomy
Exclusion Criteria:
- History of primary or secondary immunodeficiency, or patients using systemic corticosteroids or cyclosporin A
- Other cancer (including renal cell carcinoma) within the last five years (with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin)
- Embolization of the renal artery prior to nephrectomy
- Active, uncontrolled infection or other serious medical illnesses, preventing study completion, in the opinion of the Principal Investigator
Contacts and Locations More Information
Additional Information:
No publications provided
| Responsible Party: | Agenus, Inc. |
| ClinicalTrials.gov Identifier: | NCT00082459 History of Changes |
| Other Study ID Numbers: | C-100-23 |
| Study First Received: | May 10, 2004 |
| Last Updated: | September 6, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Agenus, Inc.:
|
Kidney Cancer Renal Tumor Immunotherapy |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Renal Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma |
Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013